Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351863 | 0.92 | DNM1 (0.43) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6975508 | 0.92 | DNM1 (0.50) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11765113 | 0.92 | DNM1 (0.50) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL15069 | 0.92 | CHRM2 (0.39) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11794758 | 0.90 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11328226 | 0.90 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11595499 | 0.90 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL9145047 | 0.90 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL5172690 | 0.90 | DNM1 (0.39) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL2825368 | 0.90 | KCNH2 (0.40) | DNM1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196281-B1 | METHOD FOR FLOTATION OF A SILICATE-CONTAINING IRON ORE | BASF SE (DE) | 2024-10-09 | — | — | EP | disclosed |
| US-20230249197-A1 | METHOD FOR FLOTATION OF A SILICATE-CONTAINING IRON ORE | BASF S.A. (BR) | 2023-08-10 | — | — | US | disclosed |
| US-20230249197-A1 | METHOD FOR FLOTATION OF A SILICATE-CONTAINING IRON ORE | BASF S.A. (BR) | 2023-08-10 | — | — | US | disclosed |
| EP-4196281-A1 | METHOD FOR FLOTATION OF A SILICATE-CONTAINING IRON ORE | BASF SE (DE) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034047-A1 | METHOD FOR FLOTATION OF A SILICATE-CONTAINING IRON ORE | BASF SE (DE) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022034047-A1 | METHOD FOR FLOTATION OF A SILICATE-CONTAINING IRON ORE | BASF SE (DE) | 2022-02-17 | — | — | WO | disclosed |
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-28 | — | — | US | disclosed |
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-28 | — | — | US | disclosed |
| CN-100585495-C | Lithographic printing plate precursor | EASTMAN KODAK CO | 2010-01-27 | — | — | CN | disclosed |
| US-20080213377-A1 | Delivery of Nanoparticles and/or Agents to Cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-04 | — | — | US | disclosed |
| WO-2008036139-A2 | INHIBITORS OF MSHC AND HOMOLOGS THEREOF, AND METHODS OF IDENTIFYING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-27 | — | — | WO | disclosed |
| CN-101027611-A | Lithographic printing plate precursor | EASTMAN KODAK CO (US) | 2007-08-29 | — | — | CN | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | ICMT, TST, OGA | DNM1 2324/4885MEN1 112/4885KMT2A 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.